Email Alert RSS
Volume 13 Issue 2
Mar.  2022
Turn off MathJax
Article Contents
Abstract
References
Related Articles
ZHANG Xi, HUANG Bing, WANG Guipeng. Progress of NLRP3 Inflammasome and Myocardial Ischemia Reperfusion Injury[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 296-301. DOI: 10.12290/xhyxzz.2021-0619
Citation: ZHANG Xi, HUANG Bing, WANG Guipeng. Progress of NLRP3 Inflammasome and Myocardial Ischemia Reperfusion Injury[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 296-301. DOI: 10.12290/xhyxzz.2021-0619
shu

Progress of NLRP3 Inflammasome and Myocardial Ischemia Reperfusion Injury

  • 1.

    Xinjiang Medical University, Urumqi 830000, China

  • 2.

    Wuhan University, Wuhan 430000, China

  • 3.

    Department of Cardiology, The Fifth Affiliated Hospital of Xinjiang Medical University, Urumqi 830000, China

Funds: 

Natural Science Foundation of Xinjiang Uygur Autonomous Region 2021D01C445

More Information
  • Corresponding author:

    WANG Guipeng, E-mail: WFYWGP26@163.com

  • Received Date: August 26, 2021
  • Accepted Date: September 29, 2021
  • Available Online: January 29, 2022
  • Issue Publish Date: March 29, 2022
    Graphical Abstract
    • Abstract
  • Timely recanalization of blocked coronary arteries is the key to reduce the mortality of acute myocardial infarction, but reperfusion may cause secondary injury to ischemic myocardium, namely myocardial ischemia reperfusion injury(MIRI). Nucleotide binding oligomerization domain-like receptor protein 3(NLRP3) inflammasome is involved in the whole process of MIRI by promoting cardiomyocyte scortosis, proinflammatory effects of cascade amplification and destruction of myocardial vascular endothelial cells, which has attracted extensive clinical attention. At the same time, related studies on NLRP3 inflammasome and its regulatory factors as drug targets are in full flow, which is expected to provide new ideas for the prevention and treatment of MIRI.
    • FullText(HTML)
    • References (44)
  • [1]
    胡盛涛, 高润霖, 刘力生, 等. 《中国心血管病报告2018》概要[J]. 中国循环杂志, 2019, 34: 209-220. DOI: 10.3969/j.issn.1000-3614.2019.03.001

    Hu SS, Gao RL, Liu LS, et al. Summary of The Chinese Cardiovascular Disease Report 2018[J]. Zhongguo Xunhuan Zazhi, 2019, 34: 209-220. DOI: 10.3969/j.issn.1000-3614.2019.03.001
    [2]
    Takahashi J, Yamamoto M, Yasukawa H, et al. Interleukin-22 Directly Activates Myocardial STAT3 (Signal Transducer and Activator of Transcription-3) Signaling Pathway and Prevents Myocardial Ischemia Reperfusion Injury[J]. J Am Heart Assoc, 2020, 9: e014814. DOI: 10.1161/JAHA.119.014814
    [3]
    Wang Z, Zhang SM, Xiao Y, et al. NLRP3 Inflammasome and Inflammatory Diseases[J]. Oxid Med Cell Longev, 2020, 2020: 4063562.
    [4]
    Zeng C, Wang R, Tan H. Role of pyroptosis incardiovASCular diseases and its therapeutic implications[J]. Int J Biol Sci, 2019, 15: 1345-1357. DOI: 10.7150/ijbs.33568
    [5]
    Yang X, Lin G, Han Z, et al. Structural Biology of nod-Like Receptors[J]. Adv Exp Med Biol, 2019, 1172: 119-141.
    [6]
    Lu A, Magupalli VG, Ruan J, et al. Unified polymerization mechanism for the assembly of ASC-dependent inflamma-somes[J]. Cell, 2014, 156: 1193-1206. DOI: 10.1016/j.cell.2014.02.008
    [7]
    Zheng DP, Liwinski T, Elinav E. Inflammasome activation and regulation: toward a better understanding of complex mechanisms[J]. Cell Discov, 2020, 6: 36.
    [8]
    Gong W, Shi Y, Ren J. Research progresses of molecular mechanism of pyroptosis and its related diseases[J]. Immunobiology, 2020, 225: 151884. DOI: 10.1016/j.imbio.2019.11.019
    [9]
    Hooftman A, Angiari S, Hester S, et al. The Immunomodulatory Metabolite Itaconate Modifies NLRP3 and Inhibits Inflammasome Activation[J]. Cell Metab, 2020, 32: 468-478.e7. DOI: 10.1016/j.cmet.2020.07.016
    [10]
    Guo Q, Wu Y, Hou Y, et al. Cytokine secretion and pyroptosis of thyroid follicular cells mediated by enhanced NLRP3, NLRP1, NLRC4, and AIM2 inflammasomes are associated with autoimmune thyroiditis[J]. Front Immunol, 2018, 9: 1197. DOI: 10.3389/fimmu.2018.01197
    [11]
    Yu P, Li YG, Fu WW, et al. Panax quinquefolius L. Saponins Protect Myocardial ischemia Reperfusion No-Reflow Through Inhibiting the Activation of NLRP3 Inflammasome via TLR4/MyD88/Nf-κB Signaling Pathway[J]. Front Pharmacol, 2020, 11: 607813.
    [12]
    Amin J, Boche D, Rakic S. What do we know about the inflammasome in humans?[J]. Brain Pathol, 2017, 27: 192-204. DOI: 10.1111/bpa.12479
    [13]
    Lei Q, Yi T, Chen C. NF-kappaB-Gasdermin D axis couples oxidative stress and NACHT, LRR and PYD domainscontaining protein 3 inflammasome-mediatedcardio-myocyte pyroptosis following myocardial infarction[J]. Med Sci Monit, 2018, 24: 6044-6052. DOI: 10.12659/MSM.908529
    [14]
    Minutoli L, Puzzolo D, Rinaldi M, et al. ROS-Mediated NLRP3 inflammasome activation in brain, heart, kidney, and testis ischemia/reperfusion injury[J]. Oxid Med Cell Longev, 2016, 2016: 2183026.
    [15]
    Cinteza M. OK-Flow. Sorry-No-Reflow[J]. Maedica (Bucur), 2019, 14: 323-325.
    [16]
    Dai YX, Wang S, Chang SF, et al. M2 macrophage-derived exosomes carry microRNA-148a to alleviate myocardial ischemia/reperfusion injury via inhibiting TXNIP and the TLR4/NF-κB/NLRP3 inflammasome signaling pathway[J]. J Mol Cell Cardiol, 2020, 142: 65-79. DOI: 10.1016/j.yjmcc.2020.02.007
    [17]
    Hesse J, Leberling S, Boden E, et al. CD73-derived adenosine and tenASCin-C control cytokine production by epicardium-derived cells formed after myocardial infarction[J]. FASEB J, 2017, 31: 3040-3053. DOI: 10.1096/fj.201601307R
    [18]
    Deng Y, Han X, Yao Z, et al. PPARalpha Agonist Stimulated Angiogenesis by Improving Endothelial Precursor Cell Function Via a NLRP3 Inflammasome Pathway[J]. Cell Physiol Biochem, 2017, 42: 2255-2266. DOI: 10.1159/000479999
    [19]
    Westerterp M, Fotakis P, Ouimet M, et al. Cholesterol Efflux Pathways Suppress Inflammasome Activation, NETosis, and Atherogene-sis[J]. Circulation, 2018, 138: 898-912. DOI: 10.1161/CIRCULATIONAHA.117.032636
    [20]
    Sun WJ, Dong SJ, Lu HQ, et al. Beclin-1 overexpression regulates NLRP3 activation by promoting TNFAIP3 in microvASCular injury following myocardial reperfusion[J]. Cell Signal, 2021, 84: 110008. DOI: 10.1016/j.cellsig.2021.110008
    [21]
    Zhou T, Xiang DK, Li SN, et al. MicroRNA-495 Amelio-rates Cardiac Microvascular Endothelial Cell Injury and Inflammatory Reaction by Suppressing the NLRP3 Inflamma-some Signaling Pathway[J]. Cell Physiol Biochem, 2018, 49: 798-815. DOI: 10.1159/000493042
    [22]
    van Hout GP, Bosch L, Ellenbroek GH, et al. The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction[J]. Eur Heart J, 2017, 38: 828-836.
    [23]
    Penna C, Aragno M, Cento AS, et al. Ticagrelor Conditioning Effects Are Not Additive to Cardioprotection Induced by Direct NLRP3 Inflammasome Inhibition: Role of RISK, NLRP3, and Redox Cascades[J]. Oxid Med Cell Longev, 2020, 2020: 9219825.
    [24]
    Wang L, Peng YF, Song LJ, et al. Colchicine-Containing Nanoparticles Attenuates Acute Myocardial Infarction Injury by Inhibiting Inflammation[J]. Cardiovasc Drugs Ther, 2021. doi: 10.1007/s10557-021-07239-2.
    [25]
    Opstal TSJ, Fiolet ATL, van Broekhoven A, et al. Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome[J]. J Am Coll Cardiol, 2021, 78: 859-866. DOI: 10.1016/j.jacc.2021.06.037
    [26]
    Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease[J]. N Engl J Med, 2020, 383: 1838-1847. DOI: 10.1056/NEJMoa2021372
    [27]
    Schattner A. Colchicine-new horizons for an ancient drug. Review based on the highest hierarchy of evidence[J]. Eur J Intern Med, 2022, 96: 34-41. DOI: 10.1016/j.ejim.2021.10.002
    [28]
    Leung YY, Yao Hui LL, Kraus VB. Colchicine--Update on mechanisms of action and therapeutic uses[J]. Semin Arthritis Rheum, 2015, 45: 341-350. DOI: 10.1016/j.semarthrit.2015.06.013
    [29]
    Su XL, Wang SH, Komal S, et al. The caspase-1 inhibitor VX765 upregulates connexin 43 expression and improves cell-cell communication after myocardial infarction via suppressing the IL-1β/p38 MAPK pathway[J]. Acta Pharmacol Sin, 2022. doi: 10.1038/s41401-021-00845-8.
    [30]
    Yang XM, Downey JM, Cohen MV, et al. The Highly Selective Caspase-1 Inhibitor VX-765 Provides Additive Protec-tion Against Myocardial Infarction in Rat Hearts When Combined With a Platelet Inhibitor[J]. J Cardiovasc Pharmacol Ther, 2017, 22: 574-578. DOI: 10.1177/1074248417702890
    [31]
    Do Carmo H, Arjun S, Petrucci O, et al. The Caspase 1 Inhibitor VX-765 Protects the Isolated Rat Heart via the RISK Pathway[J]. Cardiovasc Drugs Ther, 2018, 32: 165-168. DOI: 10.1007/s10557-018-6781-2
    [32]
    Luo YF, Xiong BJ, Liu HP, et al. Koumine Suppresses IL-1β Secretion and Attenuates Inflammation Associated With Blocking ROS/NF-κB/NLRP3 Axis in Macrophages[J]. Front Pharmacol, 2020, 11: 622074.
    [33]
    Nazir S, Gadi I, Al-Dabet MM, et al. Cytoprotective activated protein C averts NLRP3 inflammasome-induced ischemia-reperfusion injury via mTORC1 inhibition[J]. Blood, 2017, 130: 2664-2677. DOI: 10.1182/blood-2017-05-782102
    [34]
    Jun JH, Shim JK, Oh JE, et al. Protective Effect of Ethyl Pyruvate against Myocardial Ischemia Reperfusion Injury through Regulations of ROS-Related NLRP3 Inflammasome Activation[J]. Oxid Med Cell Longev, 2019, 2019: 4264580.
    [35]
    Lu QY, Ma JQ, Duan YY, et al. Carthamin Yellow Protects the Heart Against Ischemia/Reperfusion Injury With Reduced Reactive Oxygen Species Release and Inflammatory Response[J]. J Cardiovasc Pharmacol, 2019, 74: 228-234. DOI: 10.1097/FJC.0000000000000710
    [36]
    Chen A, Chen ZW, Xia Y, et al. Liraglutide attenuates NLRP3 inflammasome-dependent pyroptosis via regulating SIRT1/NOX4/ROS pathway in H9c2 cells[J]. Biochem Biophys Res Commun, 2018, 499: 267-272. DOI: 10.1016/j.bbrc.2018.03.142
    [37]
    Sun Q, Fan J, Billiar TR, et al. Inflammasome and autophagy regulation a two-way street[J]. Mol Med, 2017, 23: 188-195.
    [38]
    Iyer SS, He Q, Janczy JR, et al. Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation[J]. Immunity, 2013, 39: 311-323. DOI: 10.1016/j.immuni.2013.08.001
    [39]
    Li J, Zhao CT, Zhu Q, et al. Sweroside Protects Against Myocardial ischemia-Reperfusion Injury by Inhibiting Oxidative Stress and Pyroptosis Partially via Modulation of the Keap1/Nrf2 Axis[J]. Frontcardiovasc Med, 2021, 8: 650368.
    [40]
    Guo X, Hu S, Liu JJ, et al. Piperine protects against pyroptosis in myocardial ischaemia/reperfusion injury by regulating the mir-383/RP105/AKT signalling pathway[J]. J Cell Mol Med, 2021, 25: 244-258. DOI: 10.1111/jcmm.15953
    [41]
    Zuo W, Tian R, Chen Q, et al. miR-330-5p inhibits NLRP3 inflammasome mediated myocardial ischaemia-reperfusion injury by targeting TIM3[J]. Cardiovasc Drugs Ther, 2021, 35: 691-705. DOI: 10.1007/s10557-020-07104-8
    [42]
    Jiang S, Cui H, Wu P, et al. Botany, traditional uses, phytochemistry, pharmacology and toxicology of Ilex pubescens Hook et Arn[J]. J Ethnopharmacol, 2019, 245: 112147. DOI: 10.1016/j.jep.2019.112147
    [43]
    Cheng YY, Cheng LK, Gao X, et al. Covalent modification of Keap1 at Cys77 and Cys434 by pubescenoside a sup-presses oxidative stress-induced NLRP3 inflammasome activation in Myocardial ischemia-reperfusion injury[J]. Theranostics, 2021, 11: 861-877. DOI: 10.7150/thno.48436
    [44]
    Xiao Y, Oumarou DB, Wang S, et al. Malva Sylvestris Circular RNA Involved in the Protective Effect of Malva Sylvestris L. on Myocardial ischemic/Re-Perfused Injury[J]. Front Pharmacol, 2020, 11: 520486. DOI: 10.3389/fphar.2020.520486
    • Related Articles

  • Related Articles

    [1]LEI Zhenyun, XUE Guozhong, LIU Zhenhua, ZHANG Xinli. Research progress on action mechanism of NLRP3 inflammasome and pyroptosis in diabetic nephropathy[J]. Medical Journal of Peking Union Medical College Hospital. DOI: 10.12290/xhyxzz.2024-0543
    [2]GAO Jiawei, DENG Xinkai, HAN Xiaobo, LI Xiao, CHAI Yahao, ZHANG Lei. Correlation of Inflammasomes with Pyroptosis and Effect on Coagulation Function[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(6): 1395-1400. DOI: 10.12290/xhyxzz.2024-0012
    [3]WANG Caihong, LIU Rongxin, TANG Feng, WEI Xiaotao, XU Ziqing, HOU Huaijing, ZHANG Jie, ZHAO Yongqiang, XUE Jianjun. Research Progress on the Role of NLRP3 Inflammasome and Microglia in Cognitive Impairment[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(6): 1282-1288. DOI: 10.12290/xhyxzz.2023-0217
    [4]LIU Huan, HUANG Xiaoling, DAI Mengying, GUO Jiejie, GAO feng. Clinical Characteristics and Inflammatory Markers of Omicron BA.5.2 Variant Infection in Hospitalized Patients and Their Predictive Role in Disease Prognosis[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 1038-1045. DOI: 10.12290/xhyxzz.2023-0055
    [5]Liang WANG, Zhu-jun SHEN. Intramyocardial Haemorrhage after Acute Myocardial Infarction[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(2): 170-173. DOI: 10.3969/j.issn.1674-9081.20190263
    [6]Yan-meng QI, Ye-cheng LIU, Hua-dong ZHU. Predictive Value of Ranson Score for Typing Moderately Severe and Severe Hyperlipidemic Acute Pancreatitis[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(5): 489-493. DOI: 10.3969/j.issn.1674-9081.2019.05.011
    [7]Teng ZHU, Hong-zhong JIN. mRNA Expression of Methylase and Methyl-CpG Binding Protein in Peripheral Blood Mononuclear Cells from Patients with Generalized Pustular Psoriasis[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(4): 358-363. DOI: 10.3969/j.issn.1674-9081.2019.04.009
    [10]Jie LIU, Yue-ping ZENG, Chun-xia HE, Qin LONG, Hong-zhong JIN, Qiu-ning SUN. Corticosteroids plus Intravenous Immunoglobulin in the Treatment of 7 Cases with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis[J]. Medical Journal of Peking Union Medical College Hospital, 2012, 3(4): 381-385. DOI: 10.3969/j.issn.1674-9081.2012.04.004

  • Cited by

    Periodical cited type(3)

    1. 袁茂叶，王春霞，张磊. 1例血液透析合并房扑患者抗凝治疗的病例分析. 临床医学研究与实践. 2025(09): 15-18 .
    2. 张丽莉，李静，丁林锋，孙静娴，蔡静波. 颈动脉粥样硬化斑块对非瓣膜性心房颤动病人缺血性脑卒中事件的预测价值. 实用老年医学. 2024(03): 236-239 .
    3. 魏莹叶，孙玉芹. 达比加群酯联合氯吡格雷治疗高龄非瓣膜性房颤伴不稳定型心绞痛的效果观察. 中国社区医师. 2022(33): 58-60 .

    Other cited types(1)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (983) PDF downloads (73) Cited by(4)
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close